CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

By Akshay Kedari  | Date: 2020-10-12

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted strategic collaboration with Pfizer which it had announced back in September 2020.

Reportedly, Hong Kong’s Listing Committee Of The Stock Exchange had given a green light for the listing of 115,928,803 additional shares bought at a price of HK$13.37 per share by Pfizer. With this purchase, Pfizer now owns almost a 9.90 percent stake in CStone Pharmaceuticals.

According to reliable sources, CStone’s Share Subscription Agreement comes as a part of the strategic collaboration framework with Pfizer to accelerate its commercial, financial and strategic objectives as it moves to become a fully integrated biopharma firm.

After the completion of this agreement, Pfizer will have an exclusive license to commercialize CStone’s sugemalimab, one of its core late-stage assets in China and an anti-PD-L1 monoclonal antibody. Additionally, Pfizer and CStone would also be able to collaborate on the commercialization and development of additional oncology assets within the Greater China region.

Both the companies will have the option to pursue a selected basis joint in-licensing deal for supplementary oncology assets in the local market. Sources close to the matter cite that Goldman Sachs will act as CStone’s financial advisor, helping it to handle all the necessary transactions. As for legal advisors, Cooley will be representing CStone, and Clifford Chance will be representing Pfizer.

Speaking on the development, Pierre Gaudreault, Acting President, Pfizer China biopharmaceuticals group, said that this partnership builds on its longstanding history with CStone where Pfizer helped the Chinese biotech to develop a potential best-in-class PD-L1 therapy, which Pfizer will commercialize after receiving the required approval.

Besides, this new deal also strengthens its collaboration with a promising pharmaceutical firm that has remarkable clinical development capabilities.

Source Credit: http://www.cstonepharma.com/en/html/news/2470.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Apple announces new accessibility features including ‘Personal Voice’

Apple announces new accessibility features including ‘Personal Voice’

By Akshay Kedari

America’s technology giant Apple reportedly announced that it will soon launch "Personal Voice" with a new set of accessibility features. This will allow iPhone and iPad users to make their devices speak in their own voice, allowing u...

Cop28 to emphasize on health issues related climate conditions

Cop28 to emphasize on health issues related climate conditions

By Akshay Kedari

According to reliable sources, the upcoming United Nations Climate Change Conference, to be held in November 2023, will be the flagbearer for conducting a meeting of the global health ministers discussing the consequences of climate crisis on public ...

Hyundai-Kia combined earnings to exceed Toyota in a rare occurrence

Hyundai-Kia combined earnings to exceed Toyota in a rare occurrence

By Akshay Kedari

As per the reports, South Korean automaker Kia Corp., along with its parent Hyundai Motor Company, are anticipated to outperform Toyota Motor Corp. in the Q1 earnings for the first time ever. The combined operating profits for Hyundai & Kia wa...

Meta continues mass layoff spree, cuts another 4,000 jobs this week

Meta continues mass layoff spree, cuts another 4,000 jobs this week

By Akshay Kedari

Silicon Valley tech giant, Meta Platforms Inc., formerly known as Facebook, is reportedly cutting another 4,000 jobs this week in another round of mass layoffs. The latest job cuts are a part of the 10,000 layoffs announced in March. The company i...

Stoke Space unveils tracking software for development of complex hardware

Stoke Space unveils tracking software for development of complex hardware

By Akshay Kedari

Stoke Space, a space launch company, has reportedly introduced a new software tool designed to allow hardware companies to monitor the design, assessment, and integration of complex parts. Dubbed Fusion, the tool is set to target one of the most cruc...